A Phase 4 interventional study of Toujeo SoloStar and Tresiba in Type 1 Diabetes Mellitus, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 13th largest by enrollment, is one of 4 that started in 2017, is one of 24 in phase 4, and was the 53rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud is the lead sponsor of 72 studies on the registry; 23 are open to participants now.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud has 5 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates in a group of people with DM 1 the influence in parameters of oxidative stress of the treatments with the different current analogs of insulin
To evaluate by a randomized study in a group of people with DM 1 the influence in parameters of oxidative stress of the treatments with the different current analogs of
Insulin by analyzing:
Goal 2:
Study the activation of cellular pathways associated with processes and oxidation states, by means of a Array of expression of up to 50 genes encoding oxidative stress response genes as CPT1a (Carnitine Palmitoyl Transferase 1a, mitochondrial oxidizing b limiting enzyme), TAS (Fatty acyl synthetase), acetyl-coA carboxylase, Acadm (medium chain acyl dehydrogenase), Acadl (long chain acyl dehydrogenase), Acadvl (long chain acyl coA dehydrogenase), SOD1, Hmox1 and Glutamine-Cysteine ligase (Gclc).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with Tresiba insulin and NovoRapid insulin
Drug: Tresiba · Drug: NovoRapid
Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
Drug: Toujeo SoloStar · Drug: NovoRapid
Patients treated with Tresiba insulin and Humalog kwikpen insulin
Drug: Tresiba · Drug: Humalog Kwikpen
Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
Drug: Toujeo SoloStar · Drug: Humalog Kwikpen
Patients treated with Tresiba insulin and Apidra insulin
Drug: Tresiba · Drug: Apidra
Patients treated with Toujeo SoloStar insulin and Apidra insulin
Drug: Toujeo SoloStar · Drug: Apidra
Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
Also known as: Glargina U300
Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
Also known as: Degludec insulin
Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Also known as: Lispro insulin
Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Also known as: Aspart insulin
Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Also known as: Glulisine insulin
Oxidative stress markers with the new slow insulin analogues
To evaluate the impact on the circulating levels of oxidative stress markers of the different treatments using the new slow insulin analogues. 1a) Anti oxidation: Total antioxidant capacity (CAT), and 1b) Oxidation: 8-iso-prostaglandin F2 alpha (8-iso-PGF2α), thiobarbituric acid reactive substances (TBARS) and LDL-oxidized
Time frame: 6 month
HbA1c
Glycemic control: glycosylated hemoglobin
Time frame: 6 month
Mean blood glucose
Glycemic control: mean blood glucose (mg/dl)
Time frame: 6 month
Standard deviation
Glycemic variability :standard deviation \[SD\]
Time frame: 6 month
Number of mild hypoglycemia
Number of mild hypoglycaemia in two weeks
Time frame: 6 month
Number of severe hypoglycemia
Number of severe hypoglycemia in the last 6 months
Time frame: 6 month
Number of hyperglycemia
Number of hyperglycemia\> 250 mg / dl in two weeks
Time frame: 6 month
Episodes of ketosis
Episodes of ketosis in the last 6 months
Time frame: 6 month
Number os hospital admissions
Number of hospital admissions for acute diabetes decompensation in the last 6 months.
Time frame: 6 month
Quality of life questionnaire in diabetes (DQOL)
34 items on the quality of life of people with type 1 diabetes
Time frame: 6 month
Scale of adherence to treatment in patients with diabetes type 1 (DM1)
15 items related to adherence to patient treatment
Time frame: 6 month
Diabetes distress scale. DDS
17 items on the problems and stress that people with type 1 diabetes suffer (Polonski y col, 2005)
Time frame: 6 month
Fear of hypoglycemia: Questionnaire FH-15
15 items related to the fear of hypoglycemia in patients with type 1 diabetes
Time frame: 6 month
Diabetes treatment satisfaction questionnaire (DTSQ).
8 items concerning the satisfaction of the treatment
Time frame: 6 month
Plan to share: Undecided
Ran from Jan 2017 to primary completion in Nov 2020, 46 months.
Of 62 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's 46 months is above that.
Counting every sponsor, half of 74 studies reached it within 22 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Glargine · Insulin degludec · Insulin Lispro · Insulin Aspart · Insulin glulisine
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud